News and Announcements
DMX-200 Phase 2a trial meets primary end point for Chronic Kidney Disease
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DMX-200 is an adjunct therapy in which patients who are already on the standard of care angiotensin II type I receptor blocker (irbesartan) are also dosed with a chemokine receptor CCR2 blocker (propagermanium).
This Phase 2a trial was a dose escalation study in 27 patients with chronic kidney disease of a variety of causes. The primary end point was safety, with changes in biomarkers such as excess protein in the urine (proteinuria) as secondary end points. Proteinuria is a common symptom of kidney disease and is prognostic of deterioration of kidney function. High levels of protein in the urine also exacerbate the inflammation component of kidney disease, setting up a vicious cycle of disease progression.
The data released on the 12th of July from the DMX-200 Phase 2a trial was that DMX-200 has demonstrated safety and tolerability in this diverse patient population, and that in some patient groups the clinically meaningful result of 50% reduction in proteinuria was seen. This reduction was over and above the best response the patients had achieved on the standard of care therapy. These data provide the company with a wealth of information to design a more targeted Phase 2b efficacy study, and deepen engagement with potential licensing partners.
Company Updates
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Backed By Leading Investment Groups and Family Offices
